REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors.

ABSTRACT: The rise of cutting-edge precision cancer treatments has led to a growing significance of the optimal biological dose (OBD) in modern oncology trials. These trials now prioritize the consideration of both toxicity and efficacy simultaneously when determining the most desirable dosage for treatment. Traditional approaches in early-phase oncology trials have conventionally relied on the assumption of a monotone relationship between treatment efficacy and dosage. However, this assumption may not hold valid for novel oncology therapies. In reality, the dose-efficacy curve of such treatments may reach a plateau at a specific dose, posing challenges for conventional methods in accurately identifying the OBD. Furthermore, achieving reliable identification of the OBD is typically not possible base

SUBMITTER: Yang CH 

PROVIDER: S-EPMC11789924 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature